Maximus (NYSE:MMS – Get Free Report) is expected to be announcing its Q4 2025 results before the market opens on Thursday, November 20th. Analysts expect the company to announce earnings of $1.63 per share and revenue of $1.3411 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 20, 2025 at 9:00 AM ET.
Maximus Price Performance
NYSE MMS opened at $78.94 on Wednesday. The company has a quick ratio of 2.27, a current ratio of 2.27 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $4.45 billion, a PE ratio of 14.54 and a beta of 0.57. Maximus has a 12-month low of $63.77 and a 12-month high of $92.50. The company has a 50 day moving average price of $86.31 and a two-hundred day moving average price of $79.34.
Maximus Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Friday, November 14th. Maximus’s payout ratio is presently 22.10%.
Insiders Place Their Bets
Institutional Trading of Maximus
Several hedge funds have recently added to or reduced their stakes in the business. Boston Partners grew its holdings in Maximus by 47.0% in the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in Maximus by 115.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 379,342 shares of the health services provider’s stock valued at $26,630,000 after purchasing an additional 203,521 shares during the last quarter. Two Sigma Investments LP bought a new stake in Maximus in the 3rd quarter valued at $15,397,000. Balyasny Asset Management L.P. acquired a new stake in Maximus in the 2nd quarter worth $11,547,000. Finally, Bank of America Corp DE increased its holdings in shares of Maximus by 24.6% during the 3rd quarter. Bank of America Corp DE now owns 453,616 shares of the health services provider’s stock worth $41,447,000 after purchasing an additional 89,693 shares during the period. Institutional investors own 97.21% of the company’s stock.
Analyst Ratings Changes
Several equities analysts have commented on MMS shares. Zacks Research downgraded shares of Maximus from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 27th. Weiss Ratings raised Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Maximus presently has a consensus rating of “Moderate Buy” and an average price target of $90.00.
Get Our Latest Stock Report on Maximus
Maximus Company Profile
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
See Also
- Five stocks we like better than Maximus
- What is the NASDAQ Stock Exchange?
- What’s on the Thanksgiving Table? A Stock Pick for Every Course
- Election Stocks: How Elections Affect the Stock Market
- Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain
- Stock Market Sectors: What Are They and How Many Are There?
- Qualcomm’s Bulls Are Running Out of Room to Be Wrong
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
